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Abstract
Background: Some regional cross-sectional human papillomavirus (HPV) DNA prevalence data show an increase in
prevalence in older women, the reasons for which are as yet unknown. A recently published study suggests that the
increase may be at least partly due to reactivation of latent HPV in menopausal women.
Methods: We developed a dynamic mathematical model of HPV-16 transmission to estimate the key consequences
of hypothetical HPV-16 reactivation in the Australian heterosexual population. We only consider a worst case scenario
with regard to reactivation in the Australian setting when all women who are latently infected reactivate and,
wherever feasible, we choose model parameter values which may lead to a more pronounced reactivation. The
ongoing National HPV vaccination program covering both women and men is incorporated in the model.
Results: We estimate that about 1 in 10 women and men who appear to have cleared HPV-16 infection may be
latently infected. The prevalence of HPV-16 in older Australian women will increase by a factor of up to 3.1 between
now and 2025 which will be accompanied by an increase by a factor of around 1.9 in older men. However, the
long-term impact of the HPV vaccination is not significantly altered by reactivation.
Conclusions: If the reactivation hypothesis we consider is substantiated, the public health response should be
focused on further improvement of cervical screening coverage for older women. Our study also highlights the
urgent need for surveillance of HPV prevalence in older Australians.
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Background
In general, HPV DNA prevalence peaks in women aged
20–24 and then steadily declines with age. However, in
some regions the HPV age-specific prevalence curve has
been observed to be U-shaped, i.e., exhibiting an increase
in prevalence in older women (see [1-3] for detailed
reviews). We do not know whether this is the case in
Australia, as the only local prevalence data were obtained
by the Womens HPV Indigenous Non-Indigenous Urban
Rural Study (WHINURS) [4] which only enrolled women
aged 15 to 39.
It has been hypothesised that reactivation of HPV may
be at least partly responsible for the high HPV preva-
lence observed in older women (see, for example, [5,6]),
while another possibility worth consideration is changes
in sexual behaviour of men and/or women in middle-age
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[1]. In the case of Australia, the latter appears unlikely to
be responsible for a U-shaped prevalence curve, should
it be observed, as the most recently conducted compre-
hensive sexual behaviour survey (the Australian Study of
Health and Relationships (ASHR)), did not demonstrate
any notable increase in sexual activity in older Australians
[7].
Results from a recently published study by Gravitt et al.
lend plausibility to the hypothesis of HPV reactivation in
menopausal women [8], which may be happening due to
the hormonal changes altering immune function (related
findings in [9] are of interest in this context). These find-
ings may be interpreted as indicating that any menopausal
woman who has ever been infected with HPV-16 is at
risk of reactivation. In addition, the study by Gravitt
et al. speculates that a cohort effect associated with the
sexual revolution may have masked the second peak in
the age-specific HPV prevalence curves of some Western
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countries. Briefly, the idea is that due to the sexual revo-
lution and the subsequent increase in sexual activity and
HPV-16 prevalence (as compared with pre-sexual revo-
lution times), a cross-sectional study collecting HPV-16
prevalence data in the early 2000s would cover younger
women with post-sexual revolution sexual experiences
and older women whose sexual behaviour had been
defined by the pre-sexual revolution norms. While there
would be HPV-16 reactivation in these older women, it
would result in HPV-16 prevalence lower than that in the
younger women from the post-sexual revolution cohort.
Therefore, age-specific HPV-16 prevalence curves would
show no signs of HPV reactivation. However, reactivation
may be detected by prospective studies conducted when
the women who became sexually active after the sexual
revolution reach menopause.
Assuming that the above is indeed valid, we are inter-
ested in clarifying if the issue of HPV-16 reactivation
should be seen as important for the Australian public
health. To address this question, we model HPV-16 trans-
mission in the Australian heterosexual population imple-
menting reactivation of the virus in a manner we consider
to be plausible based on our current knowledge. We only
consider the worst case scenario, whereby all women at
risk of reactivation do reactivate and vaccine efficacy is
set at the lower plausible bound. We estimate the pro-
portion of women at risk of reactivation, the impact on
HPV-16 prevalence in older women and older men as a
result of reinfection of susceptible men within existing
partnerships. We also compare the long-term reductions
in HPV-16 prevalence due to the ongoing Australian HPV
vaccination program produced by the versions of our
model with and without reactivation.
Methods
Our model is briefly described below with a complete
description, including justification of assumptions, pro-
vided in Additional file 1: Technical Appendix.
Model structure and assumptions regarding HPV-16
reactivation
We developed a dynamic compartmental mathematical
model of HPV-16 transmission in the Australian hetero-
sexual population. The model is illustrated schematically
in Figure 1. This model is essentially of SIRS (Susceptible-
Infected-Removed (Immune)-Susceptible) structure with
waning natural immunity [10], extended to incorporate
the possibility that HPV-16 may enter a latent unde-
tectable state and subsequently reactivate (in women).
The SIRS structure, while not the only plausible represen-
tation of HPV natural history [11], was chosen because it
has been the most widely used (see, for example, [12] for a
review). This structure has the advantage that when natu-
ral immunity wanes very slowly, the model approximates
the SIR structure (life-long immunity) and if waning
occurs very quickly, it approaches the SIS structure (no
immunity). Our model incorporates both reactivation and
reinfection, and we do not impose a priori the extent to
which either should prevail. Susceptible women and men
in the model may become infected and then some of them
clear the infection completely and become immune, while
others enter a latent infected state in which it is assumed
that they would not test DNA positive due to viral load
falling below the detectable threshold.
The following key assumptions have been made:
• Any woman infected with HPV-16 at least once can
potentially become latently infected [8];
• All women with latent HPV-16 infection reactivate at
menopause at constant age-specific rates equal to the
rates of onset of menopause;
• Latently infected men and women are not infectious;
• Men can be latently infected in which case they are
not infectious, but they can not reactivate and cannot
be reinfected;
• The onset of menopause occurs in women aged
45–54 [13,14]
• 70% of all Australian women aged 45 to 54 are
assumed to be in the long-term partnerships [15]; this
is important because the susceptible partners of these
women can become infected without entering any
new sexual partnerships.
Assumptions regarding sexual behaviour
We assume that sexual activity in the Australian het-
erosexual population increased substantially during the
sexual revolution of 1961–1975 and then stabilised at a
level close to that described by the ASHR study in 2001–
2002. This is a necessary simplification primarily based
on public perception and backed by some sparse evidence
(see [16] for a detailed discussion). We also assume that
sexual behaviour as captured by ASHR will not change
substantially over the next 50 years or so. This may soon
prove to be an unrealistic assumption in view of the recent
data suggesting that sexually active young people have an
increasing number of sexual partners [17].
Assumptions regarding vaccination
The vaccine is assumed to be prophylactic (i.e., not ther-
apeutic and only protecting susceptible individuals from
infection), and the duration of vaccine induced protec-
tion, implemented in the model as reduced susceptibility
to reinfection, is assumed to be life-long. Vaccine cover-
age was fixed at 72% for 12 year old girls (based on 3-dose
coverage achieved thus far under the Australian vaccina-
tion program [18,19]), and at 72% for boys (since they are
vaccinated at schools along with girls, there is currently
no reason to believe their coverage will be substantially
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Figure 1 Schematic diagram of the HPV-16 transmission model for females (left) andmales (right). Here λw and λm are the forces of
infection (i.e. the rates of becoming infected) for women and men, λ¯m is an additional force of infection acting on older men whose partners
become infected via reactivation, and other parameters are as in Table 1.
less than in females). For the 2007–2009 catch-up vaccina-
tion the achieved 3-dose coverage over two years was 72%/
72%/ 62%/32% for women aged 13–15/16–17/18–19/
20–26. For the catch-up campaign for 14–15 year old boys
the 3-dose coverage was assumed to be 72% equally split
between 2013 and 2014. While the actual efficacy of the
vaccine at preventing transmission is still unknown, we
assumed the lower bounds of 80% for women [20,21] and
50% for men based on data from the clinical trials on
efficacy against persistent infection [22]. The same trials
showed that the efficacy could also be as high as 90% in
women and 80% in men, but we consider the worst case
scenario in this paper. For simplicity, and because it seems
plausible, we assume that vaccinated women are not at
risk of reactivation (see [23] for discussion).
Model calibration
The model was calibrated to the HPV-16 age-specific
prevalence in non-Indigenous Australian women aged
15–39 as reported in the WHINURS study [4]. These
data were collected in 2005–2007, hence they describe
the prevalence immediately before the commencement of
the National HPV vaccination program in 2007. HPV-16
prevalence data for men are not available for Australia.
We applied a Bayesianmethodology detailed in [24] which
entails the specification of prior probability distributions
for model parameters and these are listed in Table 1.
Results
Themeans and standard deviations of the inferred param-
eter distributions (i.e., posterior distributions) obtained
through the calibration process are shown in Table 1
and a brief description of the key observations follows.
The mean per-partnership transmission probabilities for
male-to-female transmission, βmw, and for female-to-male
transmission, βwm, inferred by the model are nearly equal
(0.93 and 0.92, respectively). It should be noted, however,
that these are usually overestimated by compartmental
models [33]. The inferred rates of clearance are marginally
higher for older men and women (as compared with the
younger men and women). The differences in these rates
are insufficient to contradict empirical estimations where
the rates are not dependent on age [27,29], though they
conflict with the higher rates for younger women reported
in [28]. On the other hand, our estimations are consistent
with findings from a large study in men which observed
that older men tended to clear HPV notably quicker than
younger men, which might be attributable to a higher
prevalence of HPV antibodies in older men [22]. The
probability (per infection) of becoming latently infected is
estimated to be at around 0.1 for both men and women.
The effect of HPV-16 reactivation in terms of tempo-
ral changes in HPV-16 DNA prevalence in the Australian
setting is illustrated in Figure 2. The model predicts that
the total sexually active male population experiences a
small overall increase in HPV-16 prevalence, but in older
men prevalence increases more substantially by a factor of
around 1.9 by the end of 2012 (since when the time of sex-
ual debut for all 45–54 year old women is after the sexual
revolution). By the same year prevalence in older women
is predicted to increase by a factor of around 3.1. A steady
decrease in prevalence begins after 2025 as women aged
26 who were covered by the catch-up vaccination in 2007
turn 45. By 2050, 72% of women aged 45–54will have been
vaccinated, so afterwards prevalence in these women is
largely stabilised. After 2055, 72% ofmen and women aged
45–54 are vaccinated, and 72% of the entiremodelled pop-
ulation is vaccinated by the end of 2060. From this point
onwards, HPV-16 prevalence, reflecting the long-term
impact of vaccination, is steady for all subpopulations.
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Table 1 Model parameters, their prior distributions (all uniform), posterior means and standard deviations (SD)
Model Prior Posterior
Parameter Symbol Specification Refs. Mean SD
Natural history parameters
Probability of HPV-16 transmission
From female to male βwm U(0.10, 1.00) [25] 0.92 0.03
From male to female βmw U(0.10, 1.00) [25] 0.93 0.03
Rate of clearance of HPV-16
For women under 30 cw1 U(0.50, 1.17) [26-29] 0.59 0.05
For women over 30 cw2 U(0.50, 1.17) [26-29] 0.60 0.05
For men under 30 cm1 U(0.55, 1.66) [30,31] 0.62 0.03
For men over 30 cm2 U(0.55, 1.66) [30,31] 0.63 0.03
Probability of becoming latently infected
For women pw U(0.01, 1.00) n/a 0.11 0.04
For men pm U(0.01, 1.00) n/a 0.09 0.05
Rate of loss of immunity
For women under 30 ww1 U(0.01, 2.00) n/a 1.65 0.16
For women over 30 ww2 U(0.01, 2.00) n/a 1.67 0.15
For men under 30 wm1 U(0.01, 2.00) n/a 1.78 0.14
For men over 30 wm2 U(0.01, 2.00) n/a 1.82 0.10
Sexual behaviour parameters
Degree of assortativity
By age group εa U(0.05, 0.95) n/a 0.27 0.22
By sexual activity group εs U(0.05, 0.95) n/a 0.64 0.21
Note that all parameters denote quantities averaged over the modelled population; the degrees of assortativity εa and εs are implemented as described in [32]; n/a
indicates that there is no published literature to inform the choice of prior distribution and the values given are based on assumption. The choice of prior distributions
is discussed in detail in Additional file 1: Technical Appendix.
Our results suggest that the prevalence achieved by vacci-
nation under the assumption of reactivation as compared
to no reactivation is visibly higher only in older women,
where it is sustained by unvaccinated women reactivating
at menopause (these will comprise 28% of all women aged
45–54). In older men, reactivation will directly affect only
those who remain unvaccinated (28% of all older men) and
susceptible while being in long-term partnerships with
unvaccinated older menopausal women. The proportion
of such men will be insignificant, hence the barely distin-
guishable difference between prevalence predicted with
and without reactivation shown in Figure 2.
Discussion
In this paper, we present a simple model-based evalua-
tion of the potential impact of reactivation of HPV-16
in Australian menopausal women in terms of changes in
HPV-16 prevalence. This is necessary for any further anal-
ysis regarding progression to cervical and other cancers in
both women and men. We focus on the strongest impact
plausible given our current limited understanding of how
reactivation may work and because from the public health
perspective evaluation of the worst case scenario is essen-
tial to assess the scale of hypothetical reactivation issue
in principle. The model we set up is adequate for our
purposes at this stage, when we effectively aim to out-
line the magnitude of the effect reactivation brings into a
model not accounting for its possibility. While intuition
suggests what should generally happen to HPV-16 preva-
lence in Australia if reactivation occurs (increase in older
women, less substantial increase in older men), mathe-
matical modelling helps to quantify this. In particular,
there is no means to estimate the proportion of latently
infected individuals except modelling.
Our results suggest that the long-term effect of reactiva-
tion will be insignificant as at the post-vaccination equilib-
rium only 28% of all women will be unvaccinated and so,
theoretically, at a risk of reactivation, but according to our
estimations only about 1/10 of these may become latently
infected. However, we are more interested in the period
when older women in the modelled population are largely
unvaccinated, which is roughly between now and early the
2030s.We conclude that reactivation has important impli-
cations for predicting the impact of vaccination in the
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Figure 2 Temporal changes in HPV-16 DNA prevalence in men and women predicted by the model with and without reactivation in
menopausal women. Solid lines are means and 95% confidence intervals are shown as shaded areas between the 2.5-th and 97.5-th percentiles.
The panels on the left-hand side show the overall prevalence in the sexually active male and female populations. The panels on the right-hand side
show prevalence in the older male and female populations where the effect of reactivation is much more pronounced.
short to medium term and for surveillance and screening
activities. The fact that from 2013 HPV-16 prevalence in
older women is predicted to nearly triple under the reac-
tivation assumption as compared to its pre-reactivation
level is a cause for concern. Similarly, the almost 60%
increase predicted in older men is of concern, since unlike
women who are covered by the National Cervical Screen-
ing Program (NCSP) [34], men are not screened. Should
sufficient clinical evidence for HPV reactivation become
available in the near future, the NCSP may have to con-
sider means to improve screening coverage among older
women. It is not clear what measures may be taken in
response to the increased prevalence in older men who
would be at an increased risk of developing HPV-16 asso-
ciated cancers (anal, penile, throat cancers) later in their
lives. Residual life expectancy for men in Australia has
been constantly growing: it reached 17.6 years for those
aged 65 in 2003 [35]. Hence, the issue of cancers in older
men can not be dismissed due to a high likelihood of them
dying in their mid-60s.
It is important to mention some limitations of our study.
Among the numerous assumptions we have made (see
Additional file 1: Technical Appendix for discussion), a
special role is played by those regarding sexual behaviour.
Our statement regarding a stable sexual behaviour after
sexual revolution should be understood as a necessary
simplification due to the absence of historical sexual
behaviour data. It is, however, acceptable. If, for exam-
ple, sexual behaviour in the Australian population in
response to AIDS declined in the 80s (similarly to what
happened in the US [36]), there would be a cohort of
menopausal women less exposed to HPV than that in
our model. As our study aims to investigate the worst
case scenario, simulating such a decline is not neces-
sary. In addition, we implicitly assume that current sexual
behaviour will remain roughly unchanged, but this is done
in all modelling studies we are aware of as it is not possible
to make robust predictions into the future. Considering
only the heterosexual population may be an omission, as
well as not considering the impact of temporary visitors,
Australian travellers overseas and immigrants. The lat-
ter is unquestionably a subject of future research since
Australia accepts high numbers of immigrants each year
[37]. We did not implement the possibility of existence of
immune memory [38] or clearly separate persistent and
incident infections (as discussed in [28,39]). Finally, we
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should stress that our study should be seen as a prelimi-
nary evaluation of the potential impact of reactivation in
Australia and is intended to estimate the worst increases
in HPV-16 prevalence due to inclusion of reactivation in
a transmission model simulating the National HPV vac-
cination program. However, as HPV reactivation remains
a hypothesis, more comprehensive reactivation modelling
studies do not yet appear timely.
Conclusions
We do not expect our findings to serve as a basis for any
immediate public health decision making. However, we
hope that our results will draw the attention of the pub-
lic health community to the subject of HPV reactivation
and serve as motivation to conduct a study focusing on
the collection of HPV-16 DNA prevalence data in older
Australian women and, if feasible, men. This study would
have to be conducted as soon as possible, as after 2025 its
relevance in the Australian setting will diminish. Any clin-
ical evidence for or against reactivation would contribute
to more efficient detection and prevention of HPV, espe-
cially in countries where HPV vaccination programs have
not yet reached their full potential.
Additional file
Additional file 1: Technical Appendix.
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